WO1999006036A1 - Use of selective rxr agonists to prevent surgical adhesions - Google Patents
Use of selective rxr agonists to prevent surgical adhesions Download PDFInfo
- Publication number
- WO1999006036A1 WO1999006036A1 PCT/US1998/015625 US9815625W WO9906036A1 WO 1999006036 A1 WO1999006036 A1 WO 1999006036A1 US 9815625 W US9815625 W US 9815625W WO 9906036 A1 WO9906036 A1 WO 9906036A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- surgical
- retinoid
- compound
- adhesions
- mmol
- Prior art date
Links
- 0 *c1cc(CCCB2)c2cc1*c(cc1)ccc1C(O)=O Chemical compound *c1cc(CCCB2)c2cc1*c(cc1)ccc1C(O)=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention is directed to methods for the minimization or prevention of post-surgical adhesion formation using agonists of the RXR retinoid receptors.
- Retinoic acid and its natural and synthetic analogs exert a wide array of biological effects. They have been shown to affect cellular growth and differentiation and are useful in a variety of dermatological and malignant conditions.
- U.S. Patent 5,534,261 discloses that retinoids, particularly all-trans retinoic acid, can be used to minimize or prevent adhesion formation following surgery. There is no disclosure, however, that selective RXR agonists would have this same utility and there is no disclosure of the particular retinoid derivatives of the present invention.
- RXR retinoid receptors are known in the literature along with suitable assays for determining if a given retinoid- like compound is considered to be a selective RXR agonist.
- U.S. Patents 5,455,265 and 5,399,586 disclose a wide variety of such compounds and their utility in the same diseases or conditions against which retinoids are useful.
- U.S. Patent 5,455,265 states that RXR selective angonists are useful as regulators of cell proliferation and differentiation, .
- dermatoses such as acne, Darier's disease, psoriasis, icthyosis, eczema and atopic dermatitis
- malignant hyperproliferative diseases such as epithelial cancer, breast cancer, prostatic cancer, head and neck cancer and myeloid leukemias, for reversing and preventing atherosclerosis and restenosis resulting from neointimal hyperproliferation, for treating and preventing other non-malignant hyperproliferative diseases such as endometrial hyperplasia, benign prostatic hypertrophy, proliferative vitreal retinopathy and dysplasias, for treating autoimmune diseases and immunological disorders (e.g.
- lupus erythematoses for treating chronic inflammatory diseases such as pulmonary fibrosis, for treating and preventing diseases associated with lipid metabolism and transport such as dyslipidemias, for promoting wound healing, for treating dry eye syndrome and for reversing and preventing the effects of sun damage to skin.
- U.S. Patent 5,399,586 discloses that RXR agonists, particularly selective RXR agonists, induce apoptosis of tumor cells.
- U.S. Patent 5,455,265 discloses a suitable assay for determining the potency of a retinoid or retinoid-like compound as an agonist at the RXR receptor sites and RAR receptor sites.
- a "selective" RXR agonist is one which is at least approximately ten times as potent as an agonist at the RXR receptor sites then at the RAR receptor sites.
- the present invention involves the finding that certain retinoid derivatives, most or all of which are selective RXR agonist compounds, have utility in preventing or minimizing post-surgical adhesion formation.
- the present invention provides a method for the minimization or prevention of post-surgical adhesion formation between organ surfaces comprising administering an effective amount of a retinoid derivative of general formula I below, most or all of which are selective RXR agonists, to a site of surgical activity on an organ surface for a period of time sufficient to permit tissue repair.
- retinoid derivatives which are the subject of the present invention have the general formula
- A is -(CR 2 ) n - wherein n is an integer of from 1 to 3;
- B and C are each independently O, S, CH 2 or C(CH 3 ) 2 ;
- R j is hydrogen or ( - ) alkyl; or a pharmaceutically acceptable salt thereof.
- Adhesion formation is a major source of postoperative morbidity and mortality.
- Appendectomy and gynecologic surgery are the most frequent surgical procedures implicated in clinically significant adhesion formation.
- the most serious complication of intraperitoneal adhesions is intestinal obstruction.
- adhesions are associated with chronic or recurrent pelvic pain and infertility in females.
- retinoids for prevention of adhesion formation is described in U.S. Patent 5,534,261. While the term “retinoid” as used in this patent is defined in several ways, no mention is made of selective RXR agonists and there is no indication that such agonists would possess this property.
- retinoid derivatives most or all of which are selective RXR agonists, possess surprisingly potent activity in preventing or minimizing adhesion formation.
- the reduction or absence of teratogenicity and skin irritation described for selective RXR agonists in the prior art See, for example, H Jiang et al, Biochemical Pharmacology Vol 50, 669-676 (1995); DM Kochhar et al, Chemico-Biological Interactions Nol 100, 1-12 (1996); C Willhite et al, Drug Metabolism Reviews Nol 28, 105-119 (1996); SM Thatcher et al, / Pharmacology and Experimental Theraputics Vol 282, 528-534 (1997); RL Beard et al, / Medicinal Chemistry Nol 39, 3556-63 (1996)) would also make such agonists more advantageous for this use than the retinoids described in U.S. Patent 5,534,261.
- the present invention provides a method for the minimization or prevention of post-surgical adhesion formation between organ surfaces comprising administering an effective amount of a retinoid derivative of general formula I above to a site of surgical activity for a period of time sufficient to permit tissue repair.
- Preferred compounds of general formula I are those wherein B and C are both C(CH 3 ) 2 , i.e.
- the compounds of the present invention have a carboxylic acid functional group and can, therefore, form salts with suitable bases. It is intended that the present invention encompass pharmaceutically acceptable salts of the compounds of formula I formed with conventional bases, i.e. both inorganic and organic bases.
- suitable salts include ammonium, alkali metal salts, particularly sodium and potassium, alkaline earth metal salts such as calcium and magnesium, and salts with suitable organic bases such as lower alkylamines (methylamine, ethylamine, cyclohexylamine, and the like) or with substituted lower alkylamines (e.g. hydroxyl-substituted alkylamines such as diethanolamine, triethanolamine or tris (hydroxymethyl) aminomethane, or with bases such as piperidine or morpholine.
- a diaryl ketone-ester, 1, is condensed with a diol, dithiol, or mixed alcohol/ thiol under acidic conditions to generate a cyclic ketal-ester, 2, whose ester group is then hydrolyzed to yield the final compound, 3.
- Example 1 4-[4-Methyl-2-(5.5,8,8-tetramethyl-5,6,7,8-tetrahydro-napthalen- 2-yl)-[1.3]dioxolan-2-yl1-benzoic acid, Compound VI
- Example 2 4-[5.5-Dimethyl-2-f5.5.8.8-tetramethyl-5.6.7.8-tetrahydro- napthalen-2-yl)-[l,3ldioxan-2-yl]-benzoic acid.
- Compound VIII 4-[5.5-Dimethyl-2-f5.5.8.8-tetramethyl-5.6.7.8-tetrahydro- napthalen-2-yl)-[l,3ldioxan-2-yl]-benzoic acid.
- the mixture was cooled to 0-5°C in an ice bath and then 1.0 ml (1.15 g; 8.1 mmol) BF 3 Et 2 0 was added via syringe.
- the reaction mixture was warmed to room temperature and stirred for 2 days.
- the mixture was diluted with EtOAc and then washed with 5% aq. Na 2 C0 3 , 5% aq.
- the mixture was cooled to 0-5°C in an ice bath and then 1.0 ml (1.15 g; 8.1 mmol) BF 3 ' Et 2 0 was added via syringe.
- the reaction mixture was warmed to room temperature and stirred for 2 days.
- the mixture was diluted with EtOAc and then washed with 5% aq.
- the retinoid derivative of the present invention may be administered by a variety of systemic and local methods.
- the compounds may be administered orally, by intravenous injection, by intramuscular injection or by intracavity instillation.
- the general range of doses will depend on the efficacy of the compound and the intended route but is expected to be from about 0.1 mg/kg to about 100 mg/kg with a preferred range of about 1 to about 25 mg/kg.
- the retinoid derivative may be administered from 72 hours prior to surgery and continue up to 2 weeks after surgery and preferably for a period 12 hours prior to surgery and continuing 48 hours after surgery.
- the retinoid derivative of the present invention can be administered in a suitable vehicle such as 5% dextrose in water adjusted to a pH to assure complete salt formation.
- a suitable vehicle such as 5% dextrose in water adjusted to a pH to assure complete salt formation.
- many other single dose delivery systems could be contemplated by those skilled in the art including microcapsules, microspheres, liposomes, viscous instilates, and polymeric delivery materials.
- the method of the present invention may be used in the prevention of surgical adhesions in any animal (mammalian) host, but is particularly preferred for use in human hosts.
- Models of peritoneal adhesions induced by surgical trauma have been used to predict the clinical activity of a number of marketed anti- adhesion barrier devices.
- One such model is the trauma-induced caecal
- caecum was exteriorized. Both sides of the caecum were abraded with a dry gauze until there was evidence of punctate bleeding. After replacing the organ in the abdominal cavity, the incision was closed. Trauma to the caecum produces fibrous scar tissue or adhesions to adjacent organs, peritoneal wall, or the omentum. Animals were treated with test compound orally or by intravenous injection or intra-abdominally by direct instillation into the peritoneal cavity. Oral treatments were administered once daily for up to 7 days. Intra-abdominal treatments were applied once post-trauma and just prior to wound closure.
- 3.0 dense, fibrous, vascularized adhesions requiring sharp dissection and covering 75% of the caecum;
- the retinoid derivatives of formula I are useful in the prevention of surgical adhesions.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU86670/98A AU733236B2 (en) | 1997-07-29 | 1998-07-28 | Use of selective RXR agonists to prevent surgical adhesions |
JP2000504850A JP2001511445A (en) | 1997-07-29 | 1998-07-28 | Use of Selective RxR Agonists to Prevent Surgical Adhesion |
CA002295807A CA2295807A1 (en) | 1997-07-29 | 1998-07-28 | Use of selective rxr agonists to prevent surgical adhesions |
EP98938064A EP1003493A4 (en) | 1997-07-29 | 1998-07-28 | Use of selective rxr agonists to prevent surgical adhesions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5401797P | 1997-07-29 | 1997-07-29 | |
US60/054,017 | 1997-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999006036A1 true WO1999006036A1 (en) | 1999-02-11 |
Family
ID=21988221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/015625 WO1999006036A1 (en) | 1997-07-29 | 1998-07-28 | Use of selective rxr agonists to prevent surgical adhesions |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1003493A4 (en) |
JP (1) | JP2001511445A (en) |
AU (1) | AU733236B2 (en) |
CA (1) | CA2295807A1 (en) |
WO (1) | WO1999006036A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6624154B1 (en) * | 1999-04-23 | 2003-09-23 | Bristol-Myers Squibb Company | Compositions and methods for treatment of hyperproliferative diseases |
EP2392971A1 (en) | 2006-11-16 | 2011-12-07 | Nikon Corporation | Surface treatment method and surface treatment apparatus, exposure method and exposure apparatus, and device manufacturing method |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1930001A4 (en) * | 2005-09-09 | 2010-07-21 | Kemphys Ltd | Pharmaceutical for use in prevention and/or treatment of bowel disease |
JP2008179570A (en) * | 2007-01-25 | 2008-08-07 | R&R Inc | Medicine for preventing and/or treating internal organ adhesion |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399586A (en) * | 1993-03-11 | 1995-03-21 | Allergan, Inc. | Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity |
US5455265A (en) * | 1993-02-11 | 1995-10-03 | Allergan, Inc. | Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors |
US5534261A (en) * | 1995-01-17 | 1996-07-09 | University Of Southern California | Retinoid-based compositions and method for preventing adhesion formation using the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU675430B2 (en) * | 1992-04-22 | 1997-02-06 | Ligand Pharmaceuticals Incorporated | Compounds having selectivity for retinoid X receptors |
JPH08506323A (en) * | 1992-11-25 | 1996-07-09 | ラ ホヤ キャンサー リサーチ ファウンデーション | RXR homodimer formation and bridged bicyclic aromatic compounds and their use in regulated gene expression |
FR2722985B1 (en) * | 1994-07-27 | 1996-09-13 | Cird Galderma | NOVEL COMPOSITIONS BASED ON A SYNERGETIC MIXTURE BETWEEN AT LEAST ONE LIGAND SPECIFIC FOR RXRS AND AT LEAST ONE LIGAND SPECIFIC FOR RAR-X OR VDR, AND USES THEREOF |
-
1998
- 1998-07-28 AU AU86670/98A patent/AU733236B2/en not_active Ceased
- 1998-07-28 CA CA002295807A patent/CA2295807A1/en not_active Abandoned
- 1998-07-28 JP JP2000504850A patent/JP2001511445A/en active Pending
- 1998-07-28 EP EP98938064A patent/EP1003493A4/en not_active Withdrawn
- 1998-07-28 WO PCT/US1998/015625 patent/WO1999006036A1/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5455265A (en) * | 1993-02-11 | 1995-10-03 | Allergan, Inc. | Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors |
US5399586A (en) * | 1993-03-11 | 1995-03-21 | Allergan, Inc. | Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity |
US5534261A (en) * | 1995-01-17 | 1996-07-09 | University Of Southern California | Retinoid-based compositions and method for preventing adhesion formation using the same |
Non-Patent Citations (1)
Title |
---|
See also references of EP1003493A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6624154B1 (en) * | 1999-04-23 | 2003-09-23 | Bristol-Myers Squibb Company | Compositions and methods for treatment of hyperproliferative diseases |
EP2392971A1 (en) | 2006-11-16 | 2011-12-07 | Nikon Corporation | Surface treatment method and surface treatment apparatus, exposure method and exposure apparatus, and device manufacturing method |
Also Published As
Publication number | Publication date |
---|---|
CA2295807A1 (en) | 1999-02-11 |
EP1003493A4 (en) | 2002-03-27 |
EP1003493A1 (en) | 2000-05-31 |
AU8667098A (en) | 1999-02-22 |
AU733236B2 (en) | 2001-05-10 |
JP2001511445A (en) | 2001-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5434295A (en) | Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds | |
FR2562539A1 (en) | NOVEL DERIVATIVES OF VINYL-4 BENZOIC ACID, PROCESS FOR PREPARING THEM AND THEIR THERAPEUTIC AND LIGAND APPLICATIONS | |
EP0946485A2 (en) | Method for treatment of dermatological disorders | |
EP0747347A1 (en) | RARy-specific retinobenzoic acid derivatives | |
NO853695L (en) | ISOXAZOLCARBOXYLIC ACID DERIVATIVES, PREPARATION AND USE THEREOF. | |
KR100466730B1 (en) | New selective retinoid agonists | |
WO1999020263A1 (en) | Thyroxine analogues having no significant hormonal activity to treat malignant tumors | |
US3649679A (en) | Substituted phenylalkanoic acid derivatives ii | |
JPH04501122A (en) | ▲Compounds and methods for the treatment of skin related to acne or psoriasis | |
JPH04270261A (en) | Isoprenoid phospholipase a2 inhibitor and preparation containing same | |
US5112986A (en) | 1-benzyl-3-hydroxymethyl-indazole compounds and derivatives | |
AU733236B2 (en) | Use of selective RXR agonists to prevent surgical adhesions | |
NO149999B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC EFFECTIVE N- (4-ACYLOXYPHENYL) -ALL-TRANS-RETINAMIDES | |
US9345678B2 (en) | Prostanoid receptor agonist compounds and methods of use for same | |
US4472430A (en) | Alpha-alkyl polyolefinic carboxylic acids and derivatives thereof useful in the treatment of psoriasis | |
AU665353B2 (en) | Cholesterol-lowering tocopherol analogs | |
CA1161044A (en) | 5-amino-tetrazole derivatives of retinoic acids, their preparation and pharmaceutical formulations containing these derivatives | |
AU704273B2 (en) | Retinoids and methods of use of same | |
PL164430B1 (en) | Method for manufacturing phenylhydrazones | |
US5925673A (en) | Benzofurans and benzopyrans as cytoprotective agents | |
US3976673A (en) | 4-Cyclopropylmethyleneoxy-3-chlorophenylacetic acid and salts thereof | |
US3860722A (en) | Hypolipidemic agents | |
EP0737476A2 (en) | A pharmaceutical preparation containing a 3-(2H)-furanone derivative for prevention and/or treatment of cataracts | |
JPS60104084A (en) | 4h-benzo(4,5)cyclohepta(1,2-b)thiophene derivative | |
EP0261565B1 (en) | Lysine salt of 4-diphenylacetic acid and its ophthalmic formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2295807 Country of ref document: CA Ref country code: CA Ref document number: 2295807 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 86670/98 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998938064 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998938064 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 86670/98 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998938064 Country of ref document: EP |